Aclaris Therapeutics, Inc. (ACRS) Form 8-K — Oct 27, 2026
Aclaris Therapeutics entered into an underwriting agreement on October 27, 2026 to sell 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares at $3.50 per share, led by Leerink Partners, Piper Sandler and Cantor Fitzgerald. The company expects approximately $46.7 million in net proceeds after underwriting discounts and expenses, with closing expected October 28, 2026. The offering, which includes pre-funded warrants exercisable at $0.00001 per share, meaningfully dilutes existing holders and extends the company's cash runway.
Key figures
- Net Income
- 0
- Gross Proceeds
- approximately $49.9 million gross (7,785,714 x $3.50 + 6,500,000 x $3.49999)
- Offering Price
- 3.5
- Shares Offered
- 7,785,714 shares plus pre-funded warrants for 6,500,000 shares
- Lockup period days
- 60
- Expected closing date
- 2026-10-28
- Net proceeds estimated
- $46.7 million
- Pre funded warrant exercise price
- $0.00001
- Underwriter purchase price per share
- $3.29
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.